Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Acute-leukemia sign may signal need for different therapy

08.09.2005


A type of chromosome change that was thought to predict a good response to treatment in patients with acute myeloid leukemia (AML) might actually signal the need for a different therapy to achieve the best outcome. The findings from this new study may alert doctors that they need to change their treatment approach for certain AML patients .

The study compared AML patients whose cancer cells showed chromosome changes known as the 8;21 translocation with patients whose cancer cells showed chromosome damage known as inversion 16.

Currently, AML patients with either the 8;21 translocation or the inversion 16 abnormalities receive the same therapy. They also tend to experience complete remission and have a better overall survival than do patients with most other subtypes of AML.



But this study found that when the two groups of patients are compared with each other – and when ethnicity, sex and other chromosome changes are considered – patients with the 8;21 abnormality fare significantly worse than do patients with inversion 16 when they receive similar therapy.

Furthermore, the researchers were surprised to find that nonwhite AML patients with the 8;21 translocation were almost six times less likely to achieve complete remission following the initial therapy than were whites.

The findings were published in a recent issue of the Journal of Clinical Oncology. They come from a Cancer and Leukemia Group B (CALGB) study initiated by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSU CCC-James).

The study is part of a larger CALGB cytogenetic trial chaired by Clara D. Bloomfield, professor of internal medicine and the William G. Pace III Professor in Cancer Research, OSU Cancer Scholar and senior adviser to the OSU Cancer Program.

“It’s widely believed that AML cases with these abnormalities have the same outcome,” says Bloomfield, “but our findings indicate that they don’t. Furthermore, nonwhites with the 8;21 translocation can do extremely poorly.

“While our data need to be verified, they strongly indicate that we must stop thinking about the 8;21 group as having a highly favorable type of leukemia and start asking what we might do to increase the cure rate among those patients. They may require a transplant or an experimental therapy after they achieve remission.”

Bloomfield was the first some years ago to determine that AML patients with the 8;12 translocation and inversion 16 abnormalities was particularly sensitive to a particular chemotherapy regimen and tended to have better outcomes than did many other AML patients.

“These findings indicate that patients with the 8;21 translocation do worse because, once they relapse, the disease doesn’t respond well to additional therapy,” says first author Guido Marcucci, associate professor of internal medicine and a hematologist with the OSU CCC-James.

“We need to begin reporting the outcomes of these patients as separate subgroups of AML, and we may need to offer them different treatments.”

This retrospective study analyzed the clinical characteristics and outcomes of 312 AML patients, 144 of whom had cancer cells with the 8;21 translocation and 168 of whom had inversion 16.

Of the 8;21-translocation patients, 100 were white (69 percent), 27 were African American (19 percent) and 12 were other ethnicities. Of the inversion-16 patients, 136 were white (82 percent), 13 were African American (8 percent) and 17 were of other ethnicities (10 percent).

The data showed that patients with the 8;21 abnormality were 1.5 times more likely to die of their disease than were patients with inversion 16.

In addition, nonwhite patients with the 8;21 translocation plus other abnormalities did extremely poorly, with 20 percent achieving long-term survival.

Among the patients who relapsed, those with the 8;21-translocation had significantly shorter survival than did the inversion-16 patients.

However, when the 8;21 translocation was the sole chromosomal abnormality among nonwhites, at least 50 percent are cured; and 76 percent of nonwhite patients were cured when the 8;21 translocation and a second abnormality, the loss of a portion of chromosome 9, were both present.

Whites with the 8;21 translocation showed 40 percent to 50 percent long-term survival in all cases.

Within the inversion-16 group, whites and nonwhites achieved complete remission equally. However, relapse was less likely in patients whose cancer cells had an extra chromosome 22 compared with patients whose cancer cells lacked an extra chromosome 22.

“Our findings need to be confirmed,” Bloomfield says. “But clearly, we want to learn more about why therapy is failing some patients so we can determine how to improve it.”

To put the above in context, about 55 percent of adult AML cases show chromosomal abnormalities. These have long been recognized as important predictors of treatment outcome. Certain of these abnormalities signal a poor response to therapy, while others signal a good response and a greater likelihood of complete remission or cure.

A chromosome inversion happens when a chromosome breaks in two places and the resulting fragment (or fragments) becomes inverted. The inversion 16 occurs when the two ends of chromosome 16 break off and become reversed.

A translocation occurs when a piece of one chromosome becomes attached to another chromosome.

Funding from the National Cancer Institute and The Coleman Leukemia Research Foundation supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://www.osu.edu

More articles from Life Sciences:

nachricht World’s Largest Study on Allergic Rhinitis Reveals new Risk Genes
17.07.2018 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Plant mothers talk to their embryos via the hormone auxin
17.07.2018 | Institute of Science and Technology Austria

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Microscopic trampoline may help create networks of quantum computers

17.07.2018 | Information Technology

In borophene, boundaries are no barrier

17.07.2018 | Materials Sciences

The role of Sodium for the Enhancement of Solar Cells

17.07.2018 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>